Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam

2018 ◽  
Vol 33 (12) ◽  
pp. 711-722 ◽  
Author(s):  
Hilary J. Navy ◽  
Linda Weffald ◽  
Thomas Delate ◽  
Rachana J. Patel ◽  
Jennifer P. Dugan
Keyword(s):  
Older Adults ◽  
Clinical Pharmacist ◽  
Pharmacist Intervention ◽  
Clinical Pharmacist Intervention

scholarly journals Cost-consequence analysis evaluating multifaceted clinical pharmacist intervention targeting patient transitions of care from hospital to primary care

2018 ◽  
Vol 2 (2) ◽  
pp. 123-130 ◽  
Author(s):  
Maja Kjaer Rasmussen ◽  
Lene Vestergaard Ravn-Nielsen ◽  
Marie-Louise Duckert ◽  
Mia Lolk Lund ◽  
Jolene Pilegaard Henriksen ◽  
...  
Keyword(s):  
Primary Care ◽  
Clinical Pharmacist ◽  
Pharmacist Intervention ◽  
Transitions Of Care ◽  
Consequence Analysis ◽  
Cost Consequence ◽  
Clinical Pharmacist Intervention

scholarly journals Evaluation of a Clinical Pharmacist Intervention on Clinical and Drug-Related Problems Among Coronary Heart Disease Inpatients: A pre-experimental prospective study at a general hospital in Indonesia

2018 ◽  
Vol 18 (1) ◽  
pp. 81 ◽  
Author(s):  
Vina A. Sagita ◽  
Anton Bahtiar ◽  
Retnosari Andrajati
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
General Hospital ◽  
Clinical Pharmacist ◽  
Drug Effects ◽  
Pharmacist Intervention ◽  
Drug Related Problems ◽  
Clinical Problems ◽  
Clinical Pharmacist Intervention

Objectives: This study aimed to evaluate the role of a clinical pharmacist intervention in decreasing subsequent clinical and drug-related problems (DRPs) among coronary heart disease (CHD) inpatients with at least one previous DRP. Methods: This pre-experimental study with a pre-post design was carried out from January to April 2017 among inpatients with at least one previous DRP at a general hospital in Tangerang District, Banten, Indonesia. Clinical and DRPs were documented prospectively by a clinical pharmacist, with DRPs classified using Version 6.2 of the DRP classification scheme of the Pharmaceutical Care Network Europe Foundation. The intervention consisted of a discussion of identified DRPs with physicians, patients, pharmaceutical logistics clerks, nurses and nutritionists. Following this, any subsequent clinical and DRPs were re-identified and further interventions were conducted as necessary. Results: A total of 75 inpatients were included in the study. Pre-intervention, there were 443 DRPs and 202 clinical problems. The most frequent DRPs were adverse drug reactions (52.6%), followed by drug effects (41.8%). Most DRPs were of moderate severity and would have resulted in moderate consequences had the pharmacist not intervened. The interventions resulted in a significant reduction in the number of DRPs, type of DRPs and number of clinical problems (P <0.05 each). Patients with complications were 26.047 times more likely to have no reduction or an increased number of clinical problems compared to patients without complications (P <0.05). Conclusion: Clinical pharmacist interventions were found to reduce subsequent DRPs and clinical problems among CHD patients with at least one previous DRP.

Use of Histamine2-Receptor Blocking Agents and Sucralfate in a Health Maintenance Organization following Continued Clinical Pharmacist Intervention

1988 ◽  
Vol 22 (6) ◽  
pp. 466-469 ◽  
Author(s):  
Robert A. Mead ◽  
William F. McGhan
Keyword(s):  
Clinical Pharmacist ◽  
Inappropriate Prescribing ◽  
Health Maintenance Organization ◽  
Pharmacist Intervention ◽  
Cost Ratio ◽  
Health Maintenance ◽  
Receptor Blocking ◽  
Blocking Agents ◽  
Clinical Pharmacist Intervention

The effect of continued clinical pharmacist intervention on the proper use of histamine2-receptor blocking agents and sucralfate in a health maintenance organization was studied. New prescriptions written for Cimetidine, famotidine, ranitidine, and sucralfate in January 1986 (preintervention), October 1986 (postintervention), and February 1987 (follow-up), and the medical record of each patient were analyzed for appropriateness using approved criteria. Clinical pharmacist intervention occurred throughout the study. There was a significant decrease (p < 0.005) in the rate of inappropriate prescribing in the postintervention (42.4 percent) and follow-up (48.7 percent) periods versus the preintervention period (81.5 percent), and in the average number of refills authorized per patient in the postintervention (1.2 ± 1.54) and follow-up (1.3 ± 1.00) periods versus the preintervention period (3.0 ± 3.67). There were no significant differences in these areas between the postintervention and follow-up periods (p > 0.05). A benefit-to-cost ratio of 4.3:1 was generated from this study which demonstrated that continued clinical pharmacy interventions can have a positive, cost-effective impact on the proper use of these commonly prescribed medications.

scholarly journals Impact of Clinical Pharmacist Intervention on the Effectiveness of a Rapid Diagnostic Test for Gram-Positive Bacteremia

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Sara Revolinski ◽  
J Njeri Wainaina ◽  
Angela Huang ◽  
Mary Beth Graham ◽  
Nathan Ledeboer ◽  
...  
Keyword(s):  
Diagnostic Test ◽  
Rapid Diagnostic Test ◽  
Clinical Pharmacist ◽  
Pharmacist Intervention ◽  
Gram Positive ◽  
Clinical Pharmacist Intervention

scholarly journals PCV122 THE IMPACT OF A CLINICAL PHARMACIST INTERVENTION ON LIPID-LOWERING IN A PRIMARY CARE SETTING

2010 ◽  
Vol 13 (7) ◽  
pp. A364
Author(s):  
N Triki ◽  
S Shani ◽  
D Rabinovich-Protter ◽  
D Mossinson ◽  
E Kokia ◽  
...  
Keyword(s):  
Primary Care ◽  
Clinical Pharmacist ◽  
Care Setting ◽  
Primary Care Setting ◽  
Pharmacist Intervention ◽  
Lipid Lowering ◽  
The Impact ◽  
Clinical Pharmacist Intervention
Sign in / Sign up

Export Citation Format

Share Document